Absci
ABSI
Performance
About Absci
Absci is a clinical-stage biopharmaceutical company that uses generative biology and computational approaches to accelerate biologics discovery. By combining cell line engineering, synthetic biology, and AI-enabled design processes, Absci aims to shorten the development timeline for therapeutic antibodies and other biologics. The company operates in the United States with a focus on novel biology to create better biologics for patients, often partnering with pharma, tech, and academic collaborators.
Recent News
Imperagen Secures $6.7M Seed Funding to Fuse Quantum Physics, AI for Faster Enzyme Engineering
Imperagen Raises £5 Million to Use Quantum Physics, AI on Enzyme Engineering
This Biotech Is Leading What Could Be a 'GLP-1 Moment for Hair Loss,' Says BTIG
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
Imperagen Secures £5 Million Seed Round to Fuse Quantum Physics, AI for Enzyme Engineering
Recent Deals
No recent deals for this company.